^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Urothelial Cancer

    Related cancers:
    18h
    BladMetrix Urine Test for Monitoring Recurrence in Non-Muscle Invasive Bladder Cancer (clinicaltrials.gov)
    P=N/A, N=500, Active, not recruiting, Oslo University Hospital
    New trial
    18h
    Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder (clinicaltrials.gov)
    P2, N=15, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Jul 2026 --> Jul 2027
    Trial completion date • Trial primary completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • urelumab (BMS-663513)
    2d
    Immunohistochemical assessment of vimentin expression and Ki-67 proliferation index in conventional urothelial carcinoma: a study of 60 Egyptian patients. (PubMed, Int Urol Nephrol)
    In this Egyptian cohort, Ki-67 ≥ 30% was strongly associated with adverse pathological features and independently predicted high-grade disease, supporting its use as a practical ancillary marker and providing regional validation of prior reports. Vimentin was not significantly associated with the studied parameters in this dataset. Future studies should assess alternative cutoffs within the same cohort and validate outcome-linked thresholds in longitudinal datasets.
    Journal
    |
    VIM (Vimentin)
    5d
    TASUC-Neo: Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant (clinicaltrials.gov)
    P1, N=2, Terminated, Brown University | N=32 --> 2 | Trial completion date: Jan 2032 --> Oct 2025 | Recruiting --> Terminated | Trial primary completion date: Jan 2027 --> Jul 2025; Principal Investigator left institution
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    AR (Androgen receptor)
    |
    AR positive
    |
    cisplatin • gemcitabine • Firmagon (degarelix)
    5d
    ZM008-001: This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=100, Recruiting, Zumutor Biologics Inc. | N=33 --> 100
    Enrollment change
    |
    Loqtorzi (toripalimab-tpzi) • ZM008
    5d
    KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04) (clinicaltrials.gov)
    P1/2, N=55, Recruiting, Merck Sharp & Dohme LLC
    Trial initiation date
    |
    Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv) • MK-3120
    6d
    Targeting TPX2-dependent lineage plasticity by CDK4/6 inhibition reverses therapy resistance in neuroendocrine bladder carcinoma. (PubMed, Cell Rep Med)
    In preclinical patient-derived organoids (PDOs) and patient-derived xenograft (PDX) models, CDK4/6 inhibition plus immune checkpoint blockade demonstrates potent antitumor efficacy. Overall, our findings suggest this combination therapy as a promising therapeutic strategy for TPX2high and NEBC patients.
    Journal
    |
    CD8 (cluster of differentiation 8)
    6d
    Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma (clinicaltrials.gov)
    P=N/A, N=36, Not yet recruiting, Peking University First Hospital
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    6d
    Photodynamic Diagnosis of Upper Tract Urothelial Carcinoma Using Fluorescence Endoscopy and Oral 5-ALA (clinicaltrials.gov)
    P2, N=10, Recruiting, Henry Ford Health System | Not yet recruiting --> Recruiting | Trial completion date: Mar 2026 --> Jan 2028 | Initiation date: May 2025 --> Apr 2026 | Trial primary completion date: Dec 2025 --> Dec 2027
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    6d
    SHIELD: Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy (clinicaltrials.gov)
    P2, N=20, Recruiting, Xiujuan Qu
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression
    |
    Herceptin (trastuzumab) • oxaliplatin • Hetronifly (serplulimab)
    7d
    Recent advances in immunotherapy for bladder cancer: mechanisms, clinical applications, and future perspectives. (PubMed, Front Oncol)
    Biomarkers predictive of treatment response-including PD-L1 expression and tumor mutational burden-are summarized, integrating recent clinical and translational evidence. We conclude by outlining future research directions focused on overcoming therapeutic resistance, refining predictive and prognostic biomarkers, and developing next-generation immunotherapies to improve clinical outcomes for patients.
    Review • Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • FOLR1 ( Folate receptor alpha ) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    PD-L1 expression
    7d
    High-Grade Urothelial Carcinoma with Divergent Prostatic Differentiation Mimicking a Collision Tumor in a Bladder Diverticulum. (PubMed, Int J Surg Pathol)
    These findings suggest that the two components are part of the same neoplastic process and, given the presence of urothelial carcinoma in situ, possibly represent the first reported example of urothelial carcinoma with divergent prostatic differentiation. Awareness of divergent differentiation in urothelial carcinomas has important diagnostic, prognostic and therapeutic implications and can be resolved with the use of ancillary molecular studies.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • RB1 (RB Transcriptional Corepressor 1) • KMT2D (Lysine Methyltransferase 2D) • DDR2 (Discoidin domain receptor 2) • GATA3 (GATA binding protein 3) • NKX3-1 (NK3 homeobox 1)